Ely Benaim Biography and Net Worth

Insider of NovoCure

Dr. Ely Benaim joined Novocure in April 2019 and serves as Chief Medical Officer. Dr. Benaim has more than 25 years of healthcare experience, including 15 years of clinical research experience in academia, government and pharmaceutical industry, as well as extensive experience in global regulatory affairs. Dr. Benaim previously served as Chief Medical Officer at Rexahn Pharmaceuticals, where he was responsible for leading clinical development programs, and providing strategic and clinical guidance. Prior to joining Rexahn, he held senior leadership positions at Berg Pharma, Millennium Pharmaceuticals Inc./Takeda Pharmaceuticals Company and Sangamo BioSciences, Inc. Dr. Benaim received his M.D. from the Universidad Central de Venezuela, Caracas, and completed his pediatric residency training at the University of South Florida. He completed fellowships in pediatric oncology and bone marrow transplantation at St. Jude’s Children’s Research Hospital, in Memphis, Tennessee.

What is Ely Benaim's net worth?: The estimated net worth of Ely Benaim is at least $656,950.07 as of August 2nd, 2022. Dr. Benaim owns 34,631 shares of NovoCure stock worth more than $656,950 as of March 27th. This net worth estimate does not reflect any other assets that Dr. Benaim may own. Learn More about Ely Benaim's net worth.
How do I contact Ely Benaim?: The corporate mailing address for Dr. Benaim and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at investorinfo@novocure.com. Learn More on Ely Benaim's contact information.
Has Ely Benaim been buying or selling shares of NovoCure?: Ely Benaim has not been actively trading shares of NovoCure during the last ninety days. Most recently, Ely Benaim sold 437 shares of the business's stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $69.66, for a transaction totalling $30,441.42. Following the completion of the sale, the insider now directly owns 34,631 shares of the company's stock, valued at $2,412,395.46. Learn More on Ely Benaim's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Mukund Paravasthu (COO), Michael Puri (Insider), Pritesh Shah (Insider), William Vernon (Director), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 5 times. They sold a total of 3,220 shares worth more than $61,749.10. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 11/1/2024.

Ely Benaim Insider Trading History at NovoCure

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/2/2022	Sell	437	$69.66	$30,441.42	34,631
8/2/2021	Sell	536	$149.38	$80,067.68
7/30/2021	Sell	651	$158.96	$103,482.96
5/27/2021	Sell	1,833	$200.00	$366,600.00	30,887
5/10/2021	Sell	1,833	$189.65	$347,628.45	35,092
4/13/2021	Sell	5,958	$200.00	$1,191,600.00	35,092
12/21/2020	Sell	2,484	$156.71	$389,267.64	31,189
7/31/2020	Sell	341	$76.39	$26,048.99
5/11/2020	Sell	1,611	$63.73	$102,669.03	16,822

Ely Benaim Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $18.97

$18.31

$19.06

50 Day Range

MA: $21.87

$18.19

$27.02

2 Week Range

Now: $18.97

$11.70

$34.13

Volume

490,446 shs

Average Volume

1,191,815 shs

Market Capitalization

$2.09 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63